10x Genomics, Inc. Form 8-K Summary
Business Context and Reporting Period
10x Genomics, Inc. filed a Current Report on Form 8-K dated October 17, 2019, with the report signed on October 18, 2019. The filing concerns a patent investigation before the U.S. International Trade Commission (ITC) and provides Regulation FD disclosure information. The company’s Class A common stock trades on Nasdaq under the symbol TXG.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes Versus the Prior Comparable Period
The ITC extended the target date for completing its investigation in the ITC 1068 Action from the previously expected timing to November 5, 2019. A final determination was expected on or before that date.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Bio-Rad Laboratories, Inc. and Lawrence Livermore National Security, LLC filed the ITC complaint in July 2017, alleging that substantially all of 10x Genomics’ products infringed five U.S. patents.
- A September 2018 Initial Determination found that the company’s GEM microfluidic chips directly infringed three patents: U.S. Patent Nos. 9,500,664, 9,636,682, and 9,649,635.
- The Initial Determination found no infringement by the company’s gel bead manufacturing microfluidic chip or Next GEM microfluidic chip with respect to the asserted claims identified in the filing.
- The judge recommended an exclusion order and cease-and-desist order affecting imported GEM microfluidic chips.
- The ITC was reviewing certain findings concerning alleged indirect infringement and the non-infringement of the gel bead manufacturing and Next GEM microfluidic chips. The filing does not state the ultimate outcome.
- An adverse final determination could affect the company’s ability to import or sell affected GEM microfluidic chips and could materially affect operations; the filing does not quantify any potential financial impact.
- The company stated that it may communicate material information through SEC filings, its website, press releases, conference calls, webcasts, and social media. Information on those channels is not incorporated by reference into this filing unless expressly stated.
Important Facts for Investors to Verify
- Verify the ITC’s final determination issued on or before November 5, 2019.
- Verify whether any exclusion order or cease-and-desist order was entered and its scope.
- Verify the commercial impact on GEM and Next GEM microfluidic chip sales, imports, and customers.
- Review subsequent filings for litigation reserves, costs, damages, injunction-related effects, or other financial consequences.
- Confirm whether later proceedings, appeals, settlements, or patent-related actions changed the company’s exposure.